Novo Nordisk Presents P-IIIa (ONWARDS 2) Trial Results of Insulin Icodec for the Treatment of Type 2 Diabetes at EASD 2022
- The P-IIIa (ONWARDS 2) trial evaluating insulin icodec (qw) vs insulin degludec (qd) in 526 patients with T2D
- The trial met its 1EPs & showed non-inferiority in reducing HbA1c, 37% vs 27% of adults achieved an HbA1c <7.0% without experiencing sev. or clinically significant hypoglycaemia @26wks., 8.17% (icodec) & 8.10% (degludec) for insulin icodec achieved a superior reduction in estimated HbA1c of 0.93% vs 0.71% for insulin degludec, patients also achieved greater treatment satisfaction when switching to insulin icodec (qw)
- The mean weekly insulin dose was 268 vs 244U/wk. while the mean change in body weight from baseline to 26wk. was 1.40kg vs –0.30kg along with the safe & well-tolerated profile with no sev. hypoglycaemia events
Ref: Novo Nordisk | Image: Novo Nordisk
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.